Edwards Lifesciences Corp EW

$105.80 -0.01 (-0.01%)

Valuation

Market cap
59,805,752,000
Revenue TTM
$6,067,600,000
Net income TTM
$1,073,500,000
P/E (trailing)
35.62
P/E (forward)
34.75
Profit margin
17.69%
Debt to equity
0.05

Trading

Volume
4,177,138
Avg volume
4,063,822
Day's range
$104.93 – $106.80
Shares out
575,000,000
Stochastic %K
99%
Beta
0.85
Analysts
Strong Buy
Price target
$111.64

Price

Company profile

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricu...

Show more

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Industry
Medical Devices
Sector
Healthcare
Phone
949 250 2500
Website
https://www.edwards.com
Address
One Edwards Way, Irvine, United States

Latest news

Stocktwits

flychicken1991 Nov 12, 9:32 PM
$EW 42-day news follow-up: +23.83% in the measured window. We posted on Oct 01 15:18 ET: FDA Approves First Heart Valve Designed to Grow with Children Original impact assessment: positive. USD 85.4400 (Oct 01 15:20 ET) -> USD 105.8000 (Nov 12 16:00 ET). First completed regular-session 5-min bar after our post to latest completed bar; Yahoo Finance. Selected for a move over 20% matching our original direction. Observed price change, not proof the news caused it or a trading return. Original dated analysis and what to watch: https://nimpact.tech/newsimpact/news/b288833a48c9e934?utm_source=stocktwits&utm_medium=story_url&utm_campaign=news_outcome_recap&utm_content=b288833a48c9e934_gt20
0 replies
openclassaction2 Nov 12, 11:32 AM
$EW the $39 million edwards lifesciences securities settlement over alleged tavr growth misstatements, about $0.66 per share, claim by dec 2, per open class actions. seems like growth stories settle too
0 replies
gassedprowler Nov 12, 1:34 AM
$EW call highlights, 👀$AVR -In the last few quarters, we gained share and our competitive position improved. But we believe that we have reached a plateau here -Bernard Zovighian: And if you look at the big picture here, this made us very confident. It is not dependent on share gains. It is truly dependent about growing the number of patients -Bernard Zovighian: Thank you. Maybe I can start at the high level, and then Dan, again, can provide some additional comments here. What we have said over the years is that over time, 👀we can expect us losing slightly some share. More competition is coming, and we all know that. 👀So if you ask me in the next 10 years, a slight loss of share, but largely offset by what we are doing to grow the market, what we are doing to have more indication, what we are doing to get into -- to make sure the penetration of TAVR is also improving. We have been saying that for a long time, and it is going to be the same, again, largely offset.
0 replies
openclassaction2 Nov 12, 12:21 AM
$EW the $39 million securities settlement, about $0.66 per share, suit alleges tavr growth was misstated, claims by dec 2, per open class actions. seems like growth guidance gets repriced in court too
0 replies
Stocktwits52wHighs Nov 11, 8:16 PM
$EW printed a new 52-week high today
0 replies
cfromhertz Nov 11, 8:00 PM
$EW Weekly Chart
0 replies
firetypecracker Nov 9, 5:23 PM
$HELP Analysts’ Top Healthcare Pick: Helus Pharma ($HELP) In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Helus Pharma, with a price target of $70.00. The company’s shares closed last Monday at $9.35. According to TipRanks.com, Trucchio is a 5-star analyst with an average return of 23.8% and a 46.6% success rate. Helus Pharma has an analyst consensus of Strong Buy, with a price target consensus of $41.71, a 351.9% upside from current levels. In a report issued on November 3, Barclays also maintained a Buy rating on the stock with a $35.00 price target. https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-edwards-lifesciences-ew-helus-pharma-help-blurbs-news $EW $NAMS $LLY
2 replies
Stocktwits52wHighs Nov 9, 4:16 PM
$EW printed a new 52-week high today
0 replies